Theralase Technologies Inc., a clinical-stage pharma company focused on energy-activated molecules for treating cancer, bacteria, and viruses, announced a grant of 7 million stock options to eligible participants. These options are exercisable at C$0.265 per share, vest over three years, and expire after five years. This move aims to incentivize and retain talent as the company advances its research and development efforts. The grant is subject to approval by the TSX Venture Exchange, reflecting ongoing efforts to fund and progress clinical studies and drug development.
The US Treasury reported a $432.3 billion deficit in July, the largest single-month shortfall since March 2021, driven by accelerated payments and rising interest costs. Year-to-date, the federal deficit stands at $1.799 trillion. The administration ...
Theralase Technologies Inc. has launched a private placement to raise between C$3 million and C$5 million by issuing units at C$0.24 each, including shares and warrants exercisable until 2031. The funds will support toxicology studies for their cance...
